BioEngine's MDCK Cell Serum-free Medium Facilitates Efficient Vaccine Production

Product features:

1.no serum, no animal source, no protein components

2. Rapid serum-free suspension adaptation of adherent MDCK cells

3.MDCK cells proliferated efficiently and were cultured at high density

4.Efficient expansion of influenza virus vaccine

 

Product advantages:

1. It has been successfully applied to several human influenza vaccine clinical projects and large-scale production of various avian influenza subtypes, significantly reducing customer production costs

2. Advanced cGMP production process to ensure excellent product batch consistency (Cpk≥1.33, RSD<5%)

3. Have ISO13485:2016 and MDSAP double quality system certification, production in line with GMP specifications

4. Provide complete supporting documents to make your application process easier

5. A technical support team with rich project experience can provide comprehensive cell culture technical support and services

 

Product performance:

Rapid suspension acclimation: Adherent MDCK cells could adapt to suspension culture quickly and grow stably with a doubling time of 18-24 hours. After acclimatization, the suspension cells were full in shape and uniform in size, and grew as single scattered cells without cell clumps.

Before and after domestication

 

High density culture:

In batch culture, MDCK cells were cultured in serum-free suspension culture, and the living cell density could reach 2.0x10⁷ cells/mL, which was much higher than that of imported brands.

 

Efficient production of avian influenza virus:

Using SF003 MDCK medium to produce H5, H7 and H9 influenza virus subtypes, HA titers ranged from 2⁹ to 2¹² HAU/25 μl, and virus titers ranged from 2⁷ to 2¹² TCID₅₀/mL.

 

Efficient production of human influenza vaccine:

The HA titer of different subtypes of human influenza virus produced by Xeno-S001 medium reached 2⁹-2¹² HAU/25μl, and the virus titer reached 2⁸-2⁹ TCID₅₀/mL.